Deborah White

Professor Deborah White

Director, Cancer Program and Deputy Theme

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Professor Deborah White PhD FFSc (RCPA)

Professor White is the Director of the Cancer Program and Deputy Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. She is a NHMRC RD Wright Biomedical Research Fellow, a Beat Cancer Prinicpal Research Fellow and Senior Principal Research Fellow with SAHMRI. She is a Professor in Health and Medical Sciences at the University of Adelaide and Health Sciences at Uni SA.

Prof White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.

Professor White is the National Flagship Lead for the ALL Stream of Australian Genomics, and SA scientific lead for Zero Children’s Cancer She is an active member of the National Health & Medical Research Council (NHMRC) being a member of the NHMRC Academy, the Translational Research Program Advisory Committee, and the Women in Health Science (WiHS) Committee. She is a member of the Editorial Board for Cancer Letters.

In 2014 she was recognised as the Australian Society for Medical Research (ASMR) Leading Light for her Medical Research and in 2016 was awarded the University of Adelaide James McWha medal. In 2019 she was awarded a prestigious NHMRC Research Excellence Award.

Leukaemia Research Group Precision Medicine Theme, Cancer Program, SAHMRI

Lead: Professor Deborah White
 

A/ RESEARCH PROJECT 1
Brief description of research area.

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a genomically complex, high-risk disease affecting both children and adults. Novel, targeted treatments are urgently required to prevent drug resistance and relapse. T-ALL is characterised by recurrent gene fusions and concomitant structural abnormalities. Ongoing advances in next generation sequencing (NGS) have enabled classification of a diverse range of genomic alterations resulting in new T-ALL subtypes. Critically, the wealth of genomic information available has identified new and recurrent genomic lesions but their biological and clinical implications remain unclear. Incorporating the knowledge gained through NGS into clinical care presents a major challenge. 

Currently, up to 30% of paediatric/adolescent T-ALL patients relapse with subsequent poor overall survival; the outcome is worse for adult patients with long-term survival rates after relapse below 10%. The over-arching focus of my studies is the generation of patient-derived xenograft (PDX) and transgenic mouse models of T-ALL from patient samples received in the laboratory. These models will be used to (1) examine re-purposing drugs and testing novel therapies; and (2) provide therapeutic options for pre-emptive intervention in the case of therapy-resistant disease. Central nervous system (CNS) involvement is common in relapsed ALL but drivers of this aggressive disease are poorly defined. This project will use imaging studies to track specific disease subtypes demonstrating CNS penetration.

Research Project 1 - Dr Laura Eadie

Title: Evaluation of leukaemic invasion and penetrancein mouse models of ALL.

Project description: 

Our laboratory is the National Referral Centre for genomic screening of ALL cases allowing identification of genomic alterations in a large number of patients.Establishment of PDX models from these patient samples is ongoing. Recent PDXs have resulted in leukaemic engraftment within the brain, indicative of CNS involvement and suggesting an aggressive disease. CNS penetration in ALL is a significant un-met clinical need, however, the pathogenesis of CNS disease, the underlying genomic determinants and the biology driving CNS penetration remain poorly understood and targeted therapies are limited.

Additional PDX models resulted in rapid detection of leukaemic cells within the blood, but not the bone marrow or brain, highlight the complexity of individual leukaemias and the need for real-time disease imaging and tracking. Fluorescently-tagged cells harvested from PDX models or transgenic cells harbouring genomic lesions of interest will be used to investigate CNS involvement. Cells isolated from leukaemic organs will be comprehensively characterised using molecular biology and NGS approaches. Surface receptor expression profiles of leukaemic cells will be examined to determine potential causes of invasion. Computational network biology analyses will be performed to define druggable pathways. Results from this project will inform on disease invasion and allow evaluation of treatment strategies for aggressive disease phenotypes in real-time.

Projects available for: Mphil / PhD

Location: SAHMRI

Research project start: Semester 1 or 2

Special requirements: Police Clearance

 

Leukaemia Research Group Precision Medicine Theme, Cancer Program, SAHMRI

Lead: Professor Deborah White
 

B/ RESEARCH PROJECT 2
Brief description of research area.

Acute Lymphoblastic Leukaemia (ALL) is the most common childhood cancer, and leading cause of non-traumatic death in children. For adolescents and young adults (AYA) with ALL the therapeutic outcomes are poor. Most older adults will die of their disease. The recent wealth of genomic information has seen the emergence of new lesions known to confer high-risk, and other recurrent fusions and gene deletions for which the biological and clinical implications remain unclear. Further, recent studies have implicated the human microbiome in ALL development, treatment response and life-long comorbidities. The major challenge is to incorporate knowledge gained through Next Generation Sequencing (NGS) into clinical care and to systematically identify druggabletargets and rational effective therapies to improve patient outcomes. To add to the complexity of therapeutic choice in ALL, immunotherapies (bi-specific T-cell engagers (BiTEs) and CAR-T cells), have shown efficacy in the relapsed/refractory setting, as a transplantation bridge. However, not all high-risk/relapsed ALL patients are eligible for immunotherapy, ~50% of patients experience severe hypersensitivity reactions and the long-term clinical sequelae remains unknown. Our laboratory is the National Referral Centre for genomic screening of ALL cases across all age groups, as such we sequence a large number of patients and have identified a significant number of alterations and novel gene fusions for investigation.

Research Project 2 – Dr Barbara McClure

Title: Cloning acute lymphoblastic leukaemia fusion genes and variants, functional characterisation and therapeutic responses.

Project description: 

Recent advances in genomic profiling have defined B-cell Acute Lymphoblastic Leukeamia (B-ALL) as a heterogeneous disease with multiple subgroups characterised by distinct genetic alterations. Many genomic lesions in B-ALL are associated with alterations of cytokine receptors or their signaling pathway mediators, transcription factors or regulators of differentiation.Genomic lesions in ALL patients stratify with prognosis and using transcriptomic analysis, we have identified a number of poorly characterisedfusion genes and variants in patients.  This project aims to clone full-length fusion-genes and gene variants from patient material into mammalian expression plasmids.  This will allow in vitrocharacterisation in cell line models of aberrant signalling pathways that drive disease and assess therapeutic responses. This project will involve a range of molecular biology and cloning techniques including primer design, PCR Sanger sequencing, bacterial work, tissue culture and flow cytometry.

Projects available for: Third Year / Honours 

Location: SAHMRI

Research project start: Semester 1

Special requirements: Police Clearance

 

Leukaemia Research Group Precision Medicine Theme, Cancer Program, SAHMRI

Lead: Professor Deborah White
 

C/ RESEARCH PROJECT 3
Brief description of research area.

Acute Lymphoblastic Leukaemia (ALL) is the most common childhood cancer, and leading cause of non-traumatic death in children. For adolescents and young adults (AYA) with ALL the therapeutic outcomes are poor. Most older adults will die of their disease. The recent wealth of genomic information has seen the emergence of new lesions known to confer high-risk, and other recurrent fusions and gene deletions for which the biological and clinical implications remain unclear. Further, recent studies have implicated the human microbiome in ALL development, treatment response and life-long comorbidities. The major challenge is to incorporate knowledge gained through Next Generation Sequencing (NGS) into clinical care and to systematically identify druggabletargets and rational effective therapies to improve patient outcomes. To add to the complexity of therapeutic choice in ALL, immunotherapies (bi-specific T-cell engagers (BiTEs) and CAR-T cells), have shown efficacy in the relapsed/refractory setting, as a transplantation bridge. However, not all high-risk/relapsed ALL patients are eligible for immunotherapy, ~50% of patients experience severe hypersensitivity reactions and the long-term clinical sequelae remains unknown. Our laboratory is the National Referral Centre for genomic screening of ALL cases across all age groups, as such we sequence a large number of patients and have identified a significant number of alterations and novel gene fusions for investigation.

Research Project 3 – Dr Sue Heatley

Title: Investigation of resistance mechanisms to the bispecific T-cell engager (BiTE)  blinatumomab in relapsed acute lymphoblastic leukaemia.

Project description: 

Recently, a new compound of drug known as Bispecific T-cell engager (BiTE) has been approved for use in B-ALL by the Food and Drug Administration (FDA) and is currently undergoing clinical trials in Australia. Blinatumomab is a BiTE that enables an immunological response between the CD19 positive leukaemic cell and a cytotoxic CD3 positive T-cell. While the introduction of blinatumomab promises to be an exciting addition to the clinical arsenal, initial response rates in relapsed/refractory ALL have been ~43% and, as with other treatments, resistance is likely to occur. Immune evasion is a likely cause of resistance as well as loss of the CD19 target, leading to CD19 negative relapse and further investigation is warranted.

Relapsed patient samples that are identified as being treated with blinatumomab will be flow sorted by CD19 positivity. CD19 positive and CD19 negative populations will undergo mRNAseq to identify if a lineage switch has occurred and if the driving event is now present in the CD19 negative population. Differences in gene expression will also be interrogated.

Resistance will be modelled in-vitroby subjecting fusion constructs to incrementally increasing doses of blinatumomab, enabling further examination of potential immune evasion pathways. 

Projects available for: Honours / Mphil / PhD

Location: SAHMRI

Research project start: Semester 1 

Special requirements: Police Clearance

    Expand
  • Appointments

    Date Position Institution name
    2017 Adjunct Professor Faculty of Health Sciences University of South Australia, Adelaide
    2015 Deputy Theme Leader (Cancer) & Director of Cancer Research South Australian Health and Medical Research Institute
    2015 Affiliate Professor Medicine University of Adelaide
    2015 Affiliate Professor Pediatrics University of Adelaide
    2015 Affiliate Professor University of Adelaide
    2015 Principal Research Fellow South Australian Health and Medical Research Institute
    2015 Group Leader South Australian Health and Medical Research Institute
    2013 Affiliate Professor Pediatrics University of Adelaide
    2013 Affiliate Professor Medicine University of Adelaide
    2013 Principal Research Fellow South Australian Health and Medical Research Institute
    2013 Director of Cancer Research South Australian Health and Medical Research Institute
    2013 Director of Cancer Research South Australian Health and Medical Research Institute, Adelaide
    2013 Principal Research Fellow South Australian Health and Medical Research Faculty
    2013 Faculty Member SA Pathology
    2011 Head of Research SA Pathology
    2011 Adjunct Associate Professor University of South Australia
    2011 Affiliate Associate Professor Medicine University of Adelaide
    2011 Chief Medical Scientist and Scientific Head University of Adelaide
    2000 Chief Medical Technician SA Pathology
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    2019 Fellowship NHMRC Research Excellence Award NHMRC Australia
    2017 Award Light the Night Blue Ambassador. Leukaemia Foundation of Australia Australia
    2016 Award Shortlisted Candidate National Academy of Science Gottschalk Medal
    2016 Award Finalist Winnovation Award (Science and Medicine Category)
    2016 Award 2016 James McWha Medalist
    2014 Award Australian Society for Medical Research (ASMR) Leading Light for 2014
    2013 Award 2013 Abstract accepted for the Presidential Symposium
    2012 Award 2012 Abstract accepted for the Presidential Symposium
    2011 Recognition Member of the Chief Investigative Team recognized by the NHMRC for one of the “Ten of the Best Project Grants” Australia
    2011 Award Centre for Cancer Biology Prize for Highest Impact Paper 2009-2010 Australia
    2009 Distinction Hanson Centre Clinical Researcher of the Year Australia
    1994 Award Travel Award for Outstanding Young Scientific Investigators Health Science Alliance Australia
    1992 Award Travel Award for Outstanding Young Scientific Investigators Health Science Alliance Australia
    1988 Recognition Outstanding Achievement in the field of Haematology University of South Australia
    1987 Award Travel Award for Outstanding Young Scientific Investigators Health Science Alliance Australia
  • Education

    Date Institution name Country Title
    2011 Faculty of Science Royal College of Pathologists Australia FFSc RCPA, Founding Fellow
    2008 The University of Adelaide Australia PhD
  • Research Interests

Peer Reviewed Research Funding

I have been successful in securing competitive research funding (Approx $30million).

International Competitive Schemes LLS (CML. 2009 and 2016) and the Hughes Foundation/USC Parker Institute (ALL 2015, 2016) NHMRC (2007 (CML),2009(CML), 2012(CML), 2012 (ALL), 2013(CML),and 2014(CML), Leukaemia Foundation of Australia (LFA) (2008 2012 (CML) and 2013 (ALL)), Cancer Council of SA (2011 (CML) and 2012 (ALL) and Channel 7 2015 (ALL). NHMRC TCR in genomics now (AGHA)(ALL $25 million). A significant outcome of the work of my group has been the successful translation into clinical practice. In excess of $5.5 million in Pharmaceutical funding over the last 10 years has been secured.

International Peer Reviewed Competitive Schemes
First Year Funded Agency Title Applicant Role Amount  
2016 Leukemia Lymphoma Society of the USA (LLS) Developing a bioassay-based algorithm for selecting frontline therapy in chronic myeloid leukemia Timothy Hughes, CIB:Deborah L White, Gerald Radich, David Yeung, Chung Kok and John Reynolds   $US600,000.00  
2015 USC Parker Institute for Childhood Cancer Research Incorporating the William Lawrence and Blanche Hughes Foundation Identification of mechanisms of drug resistance in paediatric models of Ph-like ALL treated with targeted therapies

CIA Deborah White

CIB- Charles Mullighan

$US450,000.00  
2009 Leukemia Lymphoma Society of the USA (LLS) The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to Imatinib Deborah L White, Timothy Hughes, Richard D’Andrea, Andrew Somogyi and Junia Melo   $US600,000.00  
National Peer Reviewed Competitive Schemes (Other than NHMRC)
2019 Beat Cancer Project – Principal Research Fellowship Precision Medicine in Acute Lymphobastic Leukaemia Deborah White $600,000.00 
2018 Australian Cancer Research Fund (ACRF) INFRASTRUCTURE: Australian Cancer Research Foundation Centre for Integrated Cancer Systems Biology (ACRFCICSB) CIs: Hughes, Zannettino, White, Proud, Wesselingh, Lynn, Butler, Gronthos, Tilley, Price, Worthley, Bulone $2,500,000.00 
2018 Beat Cancer Project - Infrastructure Grant INFRASTRUCTURE: A Bioinformatician for the Joint SAHMRI/AHMRI Bioinformatics Core Deborah White $234,000.00 
2018 Flinders Foundation The role of the gut microbiota in the efficacy and toxicity of agonistic antibody cancer immunotherapies Lynn D., Blake S. & White D $22,890.00 
2017 Cancer Australia Improving outcomes for high risk ALL treated with new therapies and transplant. Rosemary Sutton, Deborah White, Toby Trahair, Peter Shaw  $600,000.00 
2017 Tour de Cure Rapid Identification of High Risk Subtypes & Targeted Treatments for Children with Acute Lymphoblastic Leukaemia Toby Trahair, Rosemary Sutton, Glenn Marshall, Draga Barbaric, Luciano Dalla Pozza, Deborah White $200,000.00 
2017 Australian Research Council (ARC): LIEF Scheme INFRASTRUCTURE: Adelaide Flow Cytometry Facility. Robertson, McColl, Zannettino, Tyreman, Thompson, Mitchell, Brown, McKinnon, Hayball, Cowin, Makridis, White $480,000.00 
2017 Australian Federal Government INFRASTRUCTURE: Zero Childhood Cancer CI White (SA and SAHMRI Lead) $20,000,000.00
(Received $1,479,303.00)
2017 Anthony Rothe Memorial Trust Better Outcomes for Child & Adolescent ALL Project. Toby Trahair, Marion Mateos, Glenn Marshall, David Ziegler, Rosemary Sutton, Rishi Kotecha, Siobhan Cross, Deborah White $200,000.00
2016 PG16-01 Cancer Council NSW Program Grant Improving outcomes for children with leukaemia through molecular targeted therapies AI: White $800,000.00 
2016 Channel 7 Children’s Research Foundation High-Risk T cell ALL Laura Eadie and Deborah White $75,000.00
2016 Kids Cancer Project Single cell genomics in high-risk ALL Susan Heatley and Deborah White  $176,000.00 
2016 Beat Cancer Infrastructure Grant INFRASTRUCTURE: Transforming research into improved heatlh for patients with Leukaemia Deborah White $90,000.00
2015 Channel 7 Children’s Research Foundation Developing a robust screening tool to identify children with high risk “Ph-like” Acute Lymphoblastic Leukaemia (ALL) that will lead to improved outcomes through the use of targeted therapies Susan Heatley, Deborah White, Charles Mullighan $75,000.00
2013 Australian Cancer Research Fund (ACRF) INFRASTRUCTURE: Cancer Imaging and Therapeutics Facility CIs: Mullighan, Hughes, White, Zannettino, Gronthos, Keefe, Monro, Roder, Tilley, Price. $1,800,000.00 
2013 Leukaemia Foundation Australia  Childhood Ph-like ALL: Improving Diagnostic Screening and Therapeutic Rationale Deborah White and Prof Charles Mullighan $100,000.00 
2012 SA Cancer Research Collaborative INFRASTRUCTURE: Establishing the SA Biospecimen Respository Deborah L White (CIE) $980,000.00 
2012 Beat Cancer Project Grant Assessing the cause and drug susceptibility of Adult high-risk ALL Deborah L White, Charles Mullighan and Timothy P Hughes $80,000.00 
2012 Leukaemia Foundation Australia Characterisation of immune responses in CML patients on nilotinib and interferon alpha Yong, A, Hughes, T and White DL $100,000.00 
2012 Leukaemia Foundation Australia Developing a gene signature to predict the optimal front line kinase inhibitor for CP-CML patients Deborah White and Prof Timothy Hughes $99,254.00 
2011 Cancer Council of South Australia Developing a patient specific approach to the treatment of CP-CML with tyrosine kinase inhibitors: investigating the factors which determine response to nilotinib and dasatinib Deborah White, Richard D’Andrea, Timothy Hughes, John Rasko, Junia Vaz de Melo $92,508.00 
NHMRC Schemes (peer reviewed) (>$13 million)
2019 NHMRC Fellowship Setting a new Paradigm for Diagnosis and Therapeutic Triage in ALL using Functional Genomics Deborah White $483,404.00 
2017 NHMRC Project Grant  Chronic myeloid leukaemia: changing the treatment paradigm CI’s: Hughes, Ross, Branford, White, Yong, and Reynolds $1,162,778.08
2016 Targeted Call for Research (TCR) Genomics Translation:
Preparing Australia for Genomic Medicine: A Proposal by the Australian Genomics Health Alliance (AGHA)
Chief Investigator White(ALL Australian Flagship Lead Investigator) $25,000,000.00
(Received $1,250,000.00)
2015 NHMRC Program Grant Aberrant Signalling in Leukaemia CI’s: A. Lopez, T Hughes, M Parket AI: White, D $6,669,345.00
2014 NHMRC Project Grant Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent CIA: Timothy Hughes, CIB: Deborah White, CIC: Susan Branford, CID:David Ross, CIE:Agnes Yong $1,400,000.00 
2013 NHMRC Project Grant Screening and targeting newly discovered genetic lesions in poor risk adult and childhood ALL CIA Deborah White, CIB Charles Mullighan, CIC Timothy Hughes, CID Rosemary Sutton $718,892.85 
2012 NHMRC Project Grant Characterisation of a New Poor-Risk Sub-Category of Chronic Phase Chronic Myeloid Leukaemia CIA Deborah White, CIB Tim Hughes, CIC Richard D’Andrea $588,675.00 
2012 NHMRC Project Grant Rational development of a bioassay-based treatment algorithm for kinase inhibitor therapy in CML CIA Timothy Hughes, CIB Deborah White, CIC John Rasko $509,880.00 
2009 NHMRC Project Grant Development and assessment of novel assays to predict response to second-line TKI therapy in imatinib resistant CML CIA:Timothy Hughes, CIB: Junia Melo, CIC:Susan Branford, CID: Deborah L White $485,000.00
Industry Funding - Granted (>$5.5 million)
2015 Bristol Myers Squibb Correlative Science Proposal Associated with the DIRECT study Deborah White, David Yeung & Timothy Hughes $598,000.00 
2015 Bristol Myers Squibb Correlative Science Proposal Associated with the REGALLIA Clinical Registry Deborah White, David Yeung & Timothy Hughes $902,965.00 
2015 Celgene Correlative Science Proposal Associated with the LENI David Ross, Timothy Hughes, Deborah Whiteand Agnes Yong $440,000.00 
2014 Novartis Pharmaceuticals Australia Correlative Science Proposal Associated with the ENESTswift clinical trial Deborah White, Devendra Hiwase, Agnes Yong $500,000.00 
2014 Novartis Pharmaceuticals Australia Correlative Science Proposal Associated with the PINNACLE clinical trial Deborah White, Susan Branford, Agnes Yong, David Yeung $675,000.00 
2012 Bristol Myers Squibb Correlative Science Proposal Associated with the ALL06 clinical trial Deborah White $94,560.00 
2011 Novartis Pharmaceuticals Australia Provision of imatinib OCT-1 Activity testing for newly diagnosed CML patients Deborah White $155,925.00 
2011 Novartis Pharmaceuticals Australia Correlative Science Proposal Associated with the ENESTxtnd clinical trial Deborah White $698,255.68 
2011 Novartis Pharmaceuticals Australia Correlative Science Associated with TIDELII Clinical Trial - expansion of patient numbers Deborah White and Timothy Hughes $65,971.00 
2011 Australasian Leukaemia and Lymphoma Group Seed Funding: Investigating the Prevalence of Druggable Novel Gene Fusion, Detectable by Phospho-Flow Analysis in High Risk Adult B-ALL Deborah White, Timothy Hughes and Charles Mullighan $20,880.00 
2010 Bristol Myers Squibb RESIST Registry Timothy Hughes and Deborah White $920,000.00 
2010 Novartis Pharmaceuticals Australia Correlative Science Associated with TIDELII Clinical Trial Cohort 2 Deborah White and Timothy Hughes $659,707.91 
2009 Bristol Myers Squibb Correlative Science Proposal
Associated with the Ph+ ALL- Dasatinib clinical trial.
Deborah White and Andrew Grigg $154,919.00 
Local Schemes- Granted
2017 Contributing Haematologists Committee Research Grants Evaluate role of cellular influx and efflux pumps in Azacitidine Devendra Hiwase, Sophie Watts, Verity Saunders, Timothy Hughes, Deborah White and Amilia Wee $25,000.00 
2017 Contributing Haematologists Committee Research Grants Functional effects of mitochondrial mutations in CML David Ross and Deborah White, Ilaria Pagani and Timothy Hughes $25,000.00 
2016 Contributing Haematologists Committee Research Grants Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone David Ross and Deborah White $25,000.00
2016 Contributing Haematologists Committee Research Grants Identification of mechanisms of drug resistance in models of Ph-like ALL treated with targeted therapies David Yeung, Sue Heatley, Tessa Sadras, Tim Hughes, Deborah White $25,000.00
2015 Contributing Haematologists Committee Research Grants Digital PCR for BCR-ABL DNA in chronic myeloid leukaemia David Ross and Deborah White $30,000.00
2014 Contributing Haematologists Committee Research Grants Mitochondrial mutations in chronic myeloid leukaemia. David Ross and Deborah White $30,000.00

Undergraduate Lectures

Guest Lecturer CML Biology 3rd Year Health and Biotech, University of SA

Guest Lecturer 3rd Year Pharmacology

Guest Lecturer 3rd Year Biomedical Science 

Guest lecture series Final Year Advanced Biomedical Science + associated tutorials

Project Mentor to third year MBBS students; Research Project Design: ALL

    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2019 Co-Supervisor Evaluating the mechanism of resistance in Bcr-Abl positive leukemia cells Doctor of Philosophy Doctorate Full Time Mr Govinda Poudel
    2018 Principal Supervisor Characterising signalling cascades and investigating therapeutic targets in JAK2-rearranged acute lymphoblastic leukaemia Doctor of Philosophy Doctorate Full Time Miss Charlotte Emma-Jeane Downes
    2018 Principal Supervisor Characterisation of the impact of cytokine profiles, the microbiome and innate immunity on the response of Acute Lymphoblastic Leukaemia (ALL) patients to contemporary therapies Master of Philosophy Master Full Time Miss Stephanie Jade Field
    2018 Principal Supervisor Characterising the epigenetic profile of KMT2A and MLLT10 rearranged acute lymphoblastic leukaemia, and response to targeted therapies Master of Philosophy Master Full Time Miss Michelle Olivia Forgione
    2018 Principal Supervisor Cytokine receptor like factor 2 rearrangements (CRLF2r) are high risk in Down Syndrome Acute Lymphoblastic Leukaemia (DS ALL). This project focuses on finding a combination therapy using small molecule inhibitors to decrease the serious toxicities DS patients experience from chemotherapy. Doctor of Philosophy Doctorate Full Time Miss Elyse Chenae Page
    2017 Principal Supervisor Characterising novel genomlc lesions to develop a new comblnatlonal therapeutic strategy, in high-risk acute lymphoblastic leukaemia (ALL) categorized by JAK fusions IL-7R and polycomb repressor complex 2 mutations Doctor of Philosophy Doctorate Full Time Miss Paniz Tavakoli Shirazi
    2016 Principal Supervisor Advancing Chimeric Antigen Receptor I Cell Therapy for Myeloid Leukaemias Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Nadia El-Khawanky
  • Past Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2014 - 2018 Principal Supervisor In vitro Modelling of High-risk ALL Fusions Uncovers Genomic Alterations and Non-canonical Signalling Pathways as a Mode of TKI-Resistance - Implications for Targeted Therapy Doctor of Philosophy Doctorate Full Time Miss Kartini Asari
    2012 - 2014 Co-Supervisor The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia Master of Philosophy (Medical Science) Master Full Time Dr Oi-Lin Lee
    2012 - 2016 Principal Supervisor In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies Doctor of Philosophy Doctorate Full Time Miss Liu Lu
    2012 - 2018 Co-Supervisor Personalized Medicine Support System for Chronic Myeloid Leukaemia Patients Doctor of Philosophy Doctorate Full Time Mrs Haneen Reda M Banjar
    2010 - 2014 Co-Supervisor Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Lisa Schafranek
    2010 - 2014 Principal Supervisor Defining CP-CML patient subsets associated with poor imatinib uptake and response Doctor of Philosophy Doctorate Full Time Mr Dale Benjamin Watkins
    2009 - 2013 Co-Supervisor Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib Doctor of Philosophy Doctorate Full Time Ms Laura Eadie
    2008 - 2013 Co-Supervisor Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells Doctor of Philosophy Doctorate Full Time Miss Jueqiong Wang
    2008 - 2010 Co-Supervisor Evaluation of Anti-proliferative and Pro-apoptotic Effects of Tyrosine Kinase Inhibitors on CML-CD34+ Cells Doctor of Philosophy Doctorate Full Time Dr Devendra Hiwase
    2008 - 2011 Co-Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler
    2008 - 2012 Co-Supervisor TKI Resistance in CML Cell Lines: Investigating Resistance Pathways Doctor of Philosophy Doctorate Full Time Mrs Carine Tang
    Expand
  • Board Memberships

    Date Role Board name Institution name Country
    2016 - ongoing Member Nuclear Fuel Cycle Royal Commission Consultation and Response Advisory (CARA) Board
  • Committee Memberships

    Date Role Committee Institution Country
    2017 - ongoing Advisory Board Member Australian and New Zealand Children's Hematology/ Oncology Group Australia
    2016 - ongoing Chair ALL Stream of Australian Genomics Health Care Alliance (AGHA)
    2016 - ongoing Chair ALL Stream of the Australian Genomics Health Care Alliance (AHGA)
    2016 - ongoing Member Australian Genomics Health Care Alliance (AHGA) Executive
    2016 - ongoing Member Scientific Committee for the New Directions in Leukaemia Research Conference
    2016 - ongoing Chair SAHMRI Genomics Executive Committee
    2016 - ongoing Chair Women in Health Science Session National Directions in Leukemia Research Australia
    2016 - ongoing Chair SAHMRI Imaging Workshop South Australia Health and Medical Research Institute
    2016 - ongoing Chair Post Graduate Student Forum Basil Hetzel Institute Research Day Australia
    2016 - ongoing Founder SA Translational Cancer Research Group Meetings Australia
    2016 - ongoing Founder Statewide Cancer Translational Research Group Australia
    2016 - ongoing Member Scientific Symposium Committee South Australian Health and Medical Research Institutesa Australia
    2015 - ongoing Member Women in Science Executive Committee
    2015 - ongoing Member NHMRC Women in Health Science Faculty
    2015 - ongoing Member National Women in Health Science Faculty NHMRC Australia
    2015 - ongoing Chair Ross Wishart Memorial Award Australian Society for Medical Research Australia
    2015 - ongoing Chair CML and Myelproliferative Neoplasms HAA
    2015 - ongoing Member US Ambassadors Round Table on Scientific Innovation
    2015 - ongoing Member American Association for Cancer Research United States
    2014 - ongoing Chair Women in Science session New Directions in Leukemia Research Australia
    2014 - 2016 Member SAHMRI post graduate student Committee
    2014 - 2015 Advisory Board Member (Malignant Haematology) HAA Organising Committee Australia
    2014 - ongoing Chair Young Investigator session New Directions in Leukemia Research Australia
    2014 - ongoing Chair Women in Science session New Directions in Leukemia Research Australia
    2014 - ongoing Member SA Translational Haematology Research Group Meetings
    2014 - ongoing Member Scientific Committee for the New Directions in Leukaemia Research Conference
    2014 - ongoing Member International Chronic Myeloid Leukemia Foundation (iCMLf) Australia
    2014 - ongoing Chair CML and Myeloproliferative Neoplasm Session New Directions in Leukemia Research Australia
    2013 - ongoing Member Biosciences Pillar Committee
    2013 - ongoing Member Executive Management Committee
    2013 - ongoing Member Research Executive Committee
    2013 - ongoing Member BMS Advisory Board on Molecular Monitoring and Drug level Testing
    2013 - 2015 Founder Haematology Statewide Translational Research Group
    2013 - ongoing Member International Children's Oncology Group
    2012 - ongoing Chair ALL Stream of the Australian Genomics Health Care Alliance (AHGA) Australia
    2012 - ongoing Member • Member of the South Australian Cancer Collaborative (SACCC) Executive Committee
    2012 - ongoing Member Bioscience Pillar Committee South Australian Health and Medical Research Institute Australia
    2012 - ongoing Member Research Translational faculty NHMRC Australia
    2012 - ongoing Chair Leukaemia Foundation Early Career Scientists Session New Directions in Leukemia Research
    2012 - ongoing Member SAHMRI Bioscience Pillar Committee
    2012 - ongoing Member NHMRC Research Translational faculty
    2012 - ongoing Chair Bioscience Pillar SA Comprehensive Cancer Consortium (SACCC)
    2012 - ongoing Chair Myeloid Leukaemia Session New Directions in Leukemia Research Australia
    2012 - ongoing Member New Directions in Leukemia Research Conference
    2008 - ongoing Member Global Advisory Board Blood Level Testing and Mutational Analysis Novartis
    2008 - ongoing Member European Haematology Association
    2008 - ongoing Member American Society of Haematology United States
    2008 - ongoing Member Haematology Association of Australia and New Zealand Australia
    2008 - ongoing Member Australian Leukemia and Lymphoma Group Australia
    2000 - ongoing Member The Australasian Leukaemia & Lymphoma Group Scientific Committee
  • Memberships

    Date Role Membership Country
    2016 - ongoing Member Franklin Women
    2015 - ongoing Member American Association for Cancer Research
    2014 - ongoing Member International CML Foundation
    2013 - ongoing Member International Children’s Oncology Group (COG)
    2010 - ongoing Member Australian Leukaemia and Lymphoma Group: Laboratory Scientific Committee (only non-­clinician invited)
    2008 - ongoing Member Haematology Association of Australia and New Zealand
    2008 - ongoing Member Australian Leukaemia and Lymphoma Group (ALLG)
    2008 - ongoing Member European Haematology Association
    2008 - ongoing Member American Society of Haematology
  • Consulting/Advisories

    Date Institution Department Organisation Type Country
    2016 - ongoing Department of Premier and Cabinet DPC and CARA Legislative and political Australia
    2015 - ongoing Sigma Aldrich: Science Next Collaborative
    2013 - ongoing BMS Advisory Board on Molecular Monitoring and Drug level Testing
    2008 - ongoing Novartis Global Advisory Board Blood Level Testing and Mutational Analysis
  • Editorial Boards

    Date Role Editorial Board Name Institution Country
    2016 - ongoing Associate Editor Journal of Blood Research & Hematologic Diseases
  • Position: Director, Cancer Program and Deputy Theme
  • Phone: 0881284302
  • Email: deborah.l.white@adelaide.edu.au
  • Campus: North Terrace
  • Building: SAHMRI, floor 5
  • Org Unit: Molecular and Biomedical Science

Connect With Me
External Profiles

Other Links